№ files_lp_4_process_3_061748
File format: docx
Character count: 26056
File size: 95 KB
Year:
2023
Region / City:
Beijing, China
Subject:
Allergic diseases, monoclonal antibody therapy, clinical trials
Document Type:
Supplementary data
Institution:
Capital Medical University, Department of Immunology
Authors:
Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying
Target Population:
Children, adolescents, and adults with allergic asthma
Trial Duration:
12–60 weeks
Primary Outcomes:
Treatment safety, efficacy, quality of life, pulmonary function, IgE levels
Sample Size Range:
19–4308 participants
Medications Studied:
Omalizumab
Study Design:
Controlled clinical trials with specific inclusion criteria for allergic asthma patients
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Europe
Topic:
Allergen immunotherapy, allergic asthma, house dust mites
Document Type:
Clinical guideline
Organization / Institution:
European Academy of Allergy and Clinical Immunology (EAACI)
Authors:
I Agache, S Lau, CA Akdis, S Smolinska, M Bonini, O Cavkaytar, B Flood, P Gajdanowicz, K Izuhara, Ö Kalayci, R Mosges, O Palomares, N Papadopoulos, M Sokolowska, E Angier, M Fernandez-Rivas, G Pajno, O Pfaar, G Roberts, D Ryan, G Sturm, R van Ree, EM Varga, R Gerth van Wijk, JJ Yepes – Nuñez, M Jutel
Target Audience:
Healthcare professionals (doctors, researchers, allergy specialists)
Date Approved:
2023
Date of Revisions:
N/A
Title:
Severe Allergic Reaction – Anaphylaxis Protocol
Type of Document:
Medical Emergency Protocol
Subject:
Anaphylaxis Management
Setting:
School and School-Related Events
Target Population:
Children and Adults
Primary Medication:
Epinephrine
Additional Medication:
Albuterol Sulfate Inhalation Solution 0.083% (2.5mg/3ml)
Emergency Response:
EMS (911) Activation Required
Monitoring Requirements:
Heart Rate, Respiratory Status, pO2, Level of Consciousness
Equipment Referenced:
AED, Portable Oxygen, Ambu Bag, Pulse Oximeter, Nebulizer
Approval Authority:
Physician
Effective Date:
Not Specified
Issuing Entity:
School/District
Documentation Required:
Incident Report and Nursing Documentation
Year:
2021
Region / city:
United States
Topic:
Anaphylaxis, Epinephrine Auto-Injector, Emergency Action Plan
Document Type:
Procedure
Organization / Institution:
School, Healthcare Providers
Author:
Bingemann, T.A., Nanda, A., Russell, A.F., Butler, S.M., Boucher, E.A., Tobison, J., Phan, H., Campbell, R.L., Kelso, J.M.
Target Audience:
School Nurses, School Staff, Healthcare Providers
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Note:
Contextual Description
Year:
2023
Region / City:
Not specified
Topic:
Allergic conjunctivitis treatment
Document type:
Patient information leaflet
Author:
Ms. Alice Milligan
Target audience:
Patients suffering from allergic conjunctivitis
Approval date:
May 2023
Review date:
May 2025
Year:
2023
Region / city:
United Kingdom
Theme:
Healthcare, Allergies, Treatment Guidelines
Document type:
Patient Group Direction (PGD)
Organization:
NHS
Author:
Not specified
Target audience:
Healthcare professionals
Effective period:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Year:
2022
Journal:
World Journal of Clinical Cases
Manuscript Type:
Case Report
Authors:
Miao Zhang, Jia Chen, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li
Affiliations:
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine; Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University
Corresponding Author:
Xin Li, MD, PhD
Received Date:
May 31, 2022
Revised Date:
July 9, 2022
Accepted Date:
August 23, 2022
Published Online:
2022
Keywords:
Vitamin K1, Subcutaneous injection, Adverse reactions, Herbal medicine, Polyoxyethylated castor oil, Case report guidelines
Target Audience:
Clinicians, Dermatologists, Researchers in clinical medicine
Patient Age:
50 years
Patient Condition:
Cutaneous allergic reaction to vitamin K1
Treatment:
Chinese herbal medicine, topical and intralesional steroids
Follow-up Duration:
32 months
Year:
Not specified
Region / city:
Not specified
Topic:
Seasonal Allergic Rhinitis, Treatment Guidelines
Document type:
Medical guideline
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Healthcare professionals (GPs, clinicians)
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Note:
Year
Region / City:
United States
Topic:
Pharmaceutical naming and regulatory processes
Document type:
Application form
Organization / Institution:
United States Adopted Names Council, American Medical Association
Target audience:
Pharmaceutical companies, researchers, regulatory authorities
Year:
2023
Region / City:
Not specified
Topic:
Monoclonal antibody sequences, growth rate inhibition in cell models
Document type:
Research Supplementary Material
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Researchers, biomedical professionals
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2026
Region / City:
Canada, multiple cities
Subject:
COVID-19 treatment eligibility
Document Type:
Medical referral form
Organization / Institution:
Health Canada; regional hospitals
Author:
Clinicians completing referral
Target Audience:
Healthcare providers and eligible patients
Eligibility Criteria:
Adults and pediatric patients ≥12 years, ≥40 kg, at high risk of severe COVID-19
Treatment Window:
Within 7 days of symptom onset
Authorization:
Interim authorization (Interim Order) by Health Canada
Patient Data Fields:
Name, Date of birth, Allergies, Address, Contact information, Health Card Number
Clinical Criteria:
Symptomatic status, vaccination status, comorbidities, immunosuppression, prior COVID-19 infection
Referral Confirmation:
Clinician attestation with signature, date, and College number
Section:
Supplemental Methods
Field:
Immunology and Hematologic Malignancies
Experimental focus:
B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies:
Anti-human CD markers and related reagents for flow cytometry
Suppliers:
Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines:
THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples:
DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material:
Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system:
SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method:
Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines:
IL7; IL15
Statistical methods:
Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software:
Prism version 8 (GraphPad)
Sample origin:
Bone marrow and peripheral blood from AML patients
Animal model:
NSG mice for in vivo expansion of xenografts
Culture conditions:
RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
Year:
2026
Location:
United States
Subject:
Immunology, Monoclonal Antibodies, Mast Cell Biology
Document Type:
Research Supplement / Methods Section
Institution:
Kolltan Pharmaceuticals
Authors:
London et al.
Target Audience:
Scientific researchers in immunology and pharmacology
Experimental Period:
2026
Cell Types:
Human CD34+ progenitor cells, PBMCs, mast cells
Key Techniques:
Flow cytometry, antibody assays, cell differentiation, KIT phosphorylation
Reagents:
KTN0158, KTN0062C, KTN0209, KTN0235, Imatinib, Nilotinib, IL-3, IL-6, SCF, LDL
Year:
2026
Research area:
Molecular biology / Cancer research
Document type:
Supplementary figure
Institution:
Unspecified research laboratory
Experimental models:
A549 and HCT116 cancer cell lines
Methods:
Monoclonal antibody production, siRNA knockdown, Simple Western analysis
Compounds tested:
DMSO, M8891
Duration of treatment:
24 hours
Observation period:
96 hours post-knockdown
Controls:
Non-targeting siRNA, γ-tubulin loading control
Visualization software:
Protein Simple Compass
Year:
2024
Region / City:
Europe
Topic:
Preclinical drug safety assessment
Institution:
Master’s programme, Drug Innovation
Author:
Benedetta Boscolo Todaro
Supervisors:
Hsiao-Tzu Chien, Marieke de Bruin, Peter Van Meer
Target audience:
Regulatory scientists, pharmacologists
Study period:
October 2024 – April 2025
Data analyzed:
42 monoclonal antibodies submitted for EMA approval (2017–2024)
Methodology:
Weight-of-evidence approach, literature review, short-term toxicity studies
Ethical considerations:
Reduction of animal testing, alignment with 3Rs principles
Year:
2014
Region / city:
Bethesda, MD
Topic:
Hematology, Immunohematology, Laboratory Procedures
Document Type:
Procedure Manual
Organization / Institution:
American Association of Blood Banks
Author:
Roback JD
Target Audience:
Laboratory personnel, medical professionals
Period of validity:
Ongoing, as of revision date
Approval Date:
March 1, 2014
Date of Changes:
March 1, 2014
References:
AABB Technical Manual, 17th ed., Methods in Immunhematology 3rd ed., Standards for Hospital Transfusion Services Version 3
Scope:
The document provides instructions for the removal of antibodies from coated red blood cells using freeze-thaw elution techniques, specifically for investigating ABO hemolytic disease of the fetus and newborn.
Year:
N/A
Region / City:
N/A
Topic:
Quality Control, Blood Grouping, Antibody Screening
Document Type:
Standard Operating Procedure
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Laboratory personnel involved in blood grouping and antibody screening
Period of validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2018
Disorder Type:
Neuro-inflammatory disease
Target:
Central nervous system
Symptoms:
Optic neuritis, spinal cord inflammation, demyelination
Diagnosis:
Positive MOG antibody test, MRI evidence of demyelination
Treatment:
Immunoglobulin therapy (IVIG/SCIG), other therapies as determined by physician
Prevalence:
1 per 500,000 people
References:
Fan S et al., 2018; Kezuka T & Ishikawa H, 2018; Dos Passos GR et al., 2018; Weber MS et al., 2018
Journal:
World Journal of Gastrointestinal Pathophysiology
Manuscript Type:
Original Article
Study Design:
Retrospective Cohort Study
Authors:
Hyun Ah Chung; Sun-Young Lee; Hee Won Moon; Jeong Hwan Kim; In-Kyung Sung; Hyung Seok Park; Chan Sup Shim; Hye Seung Han
Affiliations:
Department of Internal Medicine, Department of Laboratory Medicine, and Department of Pathology, Konkuk University School of Medicine, Seoul 05030, South Korea
Corresponding Author:
Sun-Young Lee, MD, PhD
Country:
South Korea
Funding:
Supported by Konkuk University in 2015 (No. KU2015-A019-0270)
Institutional Review Board Approval:
Konkuk University School of Medicine (KUH1010625)
Clinical Trial Registration:
ClinicalTrials.gov ID: KCT0001302
Received:
December 27, 2015
Accepted:
July 11, 2016
Publication Year:
2016
Keywords:
Antibody; Helicobacter pylori; Hepatitis B; Immunoglobulin G; Pepsinogen
License:
Creative Commons Attribution Non Commercial (CC BY-NC 4.0)